Q3 2020 Spero Therapeutics Inc Earnings Call Transcript
Good day, and welcome to the Spero Therapeutics Third Quarter 2020 Financial Results Conference Call. Today's conference is being recorded. At this time, I'd like to turn the call over to Sharon Klahre, Vice President of Investor Relations and Strategic Finance. Please go ahead, ma'am.
Great. Thank you, operator, and thank you all for participating in today's conference call. Earlier today, Spero Therapeutics released financial results and provided a pipeline update for the third quarter ended September 30, 2020. If you've not yet seen the press release, it's available on the Investor page of the Spero Therapeutics website.
Before we begin, I'd like to remind you that some of the information contained in this press release and on this conference call contain forward-looking statements based on our current expectations, including statements about the initiation, timing and submission to the FDA of an NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |